ASTELLAS PHARMA

Mitsubishi Research Institute and Astellas Pharma have signed a memorandum of understanding to support Japanese drug-discovery startups in their global expansion efforts.

Nanoform Finland has commenced pivotal bioequivalence studies of Nanoenzalutamide, a nanocrystalline-enabled formulation designed as an alternative to XTANDI for prostate cancer treatment.

Astellas Pharma has entered an exclusive worldwide licensing agreement with Evopoint Biosciences for XNW27011, a clinical-stage antibody-drug conjugate targeting CLDN18.2 for solid tumors.

Vyloy (zolbetuximab) has emerged as the first approved Claudin 18.2-targeted therapy for HER2-negative gastric and gastroesophageal junction adenocarcinoma, marking a significant milestone in precision oncology.

KaliVir Immunotherapeutics has successfully completed the first cohort of its STEALTH-001 Phase 1/1b trial evaluating VET3-TGI in patients with advanced solid tumors.

A newly released global clinical trials review provides extensive data on Interstitial Cystitis research, tracking trial numbers and enrollment trends across major countries worldwide.

Post-hoc analysis of GATHER1 and GATHER2 trials reveals a clear structure-function relationship between ellipsoid zone integrity and visual acuity in geographic atrophy patients.

AviadoBio has completed dosing the second cohort in its ASPIRE-FTD clinical trial evaluating AVB-101, a gene therapy for frontotemporal dementia with GRN mutations, with plans to initiate a third cohort in Q3 2025.

Astellas will showcase nine abstracts on IZERVAY™ (avacincaptad pegol) at the ARVO and RWC ophthalmology meetings in May 2025, including two oral presentations on ellipsoid zone integrity and its relationship to vision outcomes.

Chromatin Bioscience has entered a collaboration agreement with Astellas Pharma to design cell-selective synthetic promoters using its proprietary chromatinLENS platform.